SGC stimulators
US-9309235-B2 · Apr 12, 2016 · US
sGC stimulators
US10183021B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10183021-B2 |
| Application number | US-201615245697-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 24, 2016 |
| Priority date | Mar 15, 2013 |
| Publication date | Jan 22, 2019 |
| Grant date | Jan 22, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating resistant hypertension in a subject in need of treatment, comprising administering a therapeutically effective amount of compound I-324 or a pharmaceutically acceptable salt thereof, to the subject in need of treatment; wherein the subject is on concurrent use of at least three antihypertensive agents belonging to different antihypertensive drug classes selected from the group consisting of angiotensin-converting-enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), calcium channel blocker, diuretic, and beta blocker. 2. The method of claim 1 , wherein the angiotensin-converting-enzyme (ACE) inhibitor is captopril, enalapril, ramipril, lisinopril, fosinopril, benazepril, alacepril, or delapril. 3. The method of claim 1 , wherein the angiotensin II receptor blocker (ARB) is azilsartan, irbesartan, candesartan, telmisartan, olmesartan, losartan or valsartan. 4. The method of claim 1 , wherein the calcium channel blocker is amlodipine. 5. The method of claim 1 , wherein the diuretic is hydrochlorothiazide, chlorthalidone, a potassium sparing diuretic, or an aldosterone antagonist. 6. The method of claim 1 , wherein the beta blocker is nebivolol, metoprolol or atenolol. 7. The method of claim 1 , wherein the angiotensin-converting-enzyme (ACE) inhibitor is captopril, enalapril, ramipril, lisinopril, or benazepril; the angiotensin II receptor blocker (ARB) is losartan or valsartan; the calcium channel blocker is amlodipine; the diuretic is hydrochlorothiazide; and the beta blocker is metoprolol or atenolol. 8. The method of claim 5 , wherein the potassium sparing diuretic is amiloride or triamterene. 9. The method of claim 5 , wherein the aldosterone antagonist is eplerenone or spironolactone.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
Non-condensed thiazines containing further heterocyclic rings · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10183021B2 cover?
- Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
- Who is the assignee on this patent?
- Ironwood Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/506. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).